By Chris Wack
Biophytis shares were up 84% to $1.62 after the company signed a partnership agreement with Skyepharma, a French pharmaceutical company, for the production of regulatory batches of Sarconeos for severe forms of Covid-19, with a goal of submitting marketing authorization applications.
Earlier in Monday’s session, the stock actually touched its 52-week low of 88 cents, and is down 74% in the past 12 months.
Skyepharma will develop finished product batches of Sarconeos, meeting the Good Manufacturing Practice standards required for market access filings.
The key stages in the production of Sarconeos will be done by French partners, and pharmaceutical development work at the industrial stage will complete the information required for early access authorizations, particularly in France and Brazil.
Last week, Biophytis said it is taking steps in Brazil to confirm the early access authorization for Sarconeos. This new authorization is expected by the end of the year.
Write to Chris Wack at chris.wack@wsj.com
Read the full article here